CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients

Acute Lymphoblastic Leukemia Clinical Trial

Official title:

A Phase II Study of CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients Previously Treated With Cell Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03902197
• Other study ID #: CD19hsCAR20190401
• Status: Recruiting
• Phase: Phase 2
• Start date: April 22, 2019
• Est. completion date: December 21, 2023

Study information

• Verified date: March 2019
• Source: Xuanwu Hospital, Beijing
• Contact: Zhiguo Chen, PhD
• Phone: 86-10-83198889
• Email: chenzhiguo[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase II study is to evaluate the efficacy and safety of a CD19-targeting humanized selective CAR-T (CD19 hsCAR-T) in refractory/relapsed CD19+ B-ALL leukemia patients who have no available curative treatment options, have a limited prognosis with currently available treatments, and were previously treated with a B cell directed cell therapy.

Description:

CD19+ B-ALL patients who have relapsed after murine-based CD19 CAR-T (CD19mCAR-T) treatment and/or have limited clinical response to CD19mCAR-T will be enrolled to receive CD19 hsCAR-T treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 21, 2023
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 75 Years

Eligibility

Inclusion Criteria:

1. Subjects with refractory/relapse B-cell ALL with no available curative treatment options (such as autologous or allogeneic SCT);

2. Subjects previously treated with B cell-directed engineered cell therapy are eligible if they meet the following criteria:

1. relapsed and/or MRD-positive after prior cell therapy;

2. partial response to prior cell therapy;

3. Clinical and laboratory data are available;

3. Documented CD19 expression after previous B cell-directed therapies;

4. Aged 1 to 75 years;

5. KPS>40;

6. At least 2 weeks or 5 drug half-lives, whichever is shorter must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis, except for systemic inhibitory/stimulatory immune checkpoint therapy;

7. Women of childbearing potential must have a urine pregnancy test taken and proven negative prior to the treatment. All patients agree to use reliable methods of contraception during the trial period and throughout the last follow-up visit;

8. Subjects with relapsed disease after prior allogeneic SCT (myeloablative or non-myeloablative) will be eligible if the patients do not present with active GVHD and are not undergoing immunosuppressive regimes;

9. Patients with CNS3 (WCB =5/mL in CSF with presence of lymphoblasts) disease will be eligible if the CNS disease is responsive to therapy;

10. Participation in the clinical trials should be voluntary with signed informed consent.

Exclusion Criteria:

1. Patients with hypervolemia (white blood cell count> 50 x 10^9 / L) or rapidly progressive disease that in the estimation of the investigators and sponsors would compromise the patient's ability to complete the study;

2. History of melanoma skin cancer or other primary tumors (eg, cervical cancer, bladder cancer, breast cancer) (except for those with 3 years or longer of cure);

3. Patients with fungal, bacterial, viral, or other uncontrollable infections or infections requiring Level 4 isolation (UTI or inoculation assays may be performed if necessary);

4. Patients with positive results for HIV, HBV, HCV tests;

5. With CNS disorders such as cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or autoimmune disease with CNS involvement;

6. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac diseases within 12 months of enrollment, or with cardiac atrial or cardiac ventricular lymphoma;

7. Patients that are receiving anticoagulant therapy or have ever coagulation disorders;

8. Any medical condition that in the judgment of the sponsors/investigators is likely to interfere with assessment of safety or efficacy of study;

9. History of severe immediate hypersensitivity reaction to any of the agents used in this study;

10. Female patients who are pregnant or breastfeeding;

11. Feasibility assessment during screening demonstrates <30% transduction of target lymphocytes, or insufficient expansion (< 5-fold) in response to CD3/CD28 co-stimulation;

12. Patients with any uncontrolled diseases that are unsuitable for enrollment;

13. CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity;

14. Any situation that is considered to potentially increase the risk of the subject or interfere with the outcome of the study;

15. Patients who have been enrolled in other clinical studies.

Related Conditions & MeSH terms

• Acute Lymphoblastic Leukemia
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Biological:
• CD19 hsCAR-T
CD19 hsCAR-T will be administered by I.V. infusion

Locations

Country	Name	City	State
China	Beijing Children's Hospital Capital Meidcal University	Beijing	Beijing
China	Beijing Children's Hospital, Capital Medical University	Beijing	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Xuanwu Hospital, Beijing	Beijing Children's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall response rate (ORR) within 3 months	Overall response rate (ORR) within 3 months after infusion of CD19 hsCAR-T	3 months
Secondary	Best overall response (BOR)	Best overall response (BOR) of complete remission (CR) or CR with incomplete blood count recovery (CRi) within 3 months after CD19 hsCAR-T infusion	3 months
Secondary	Duration of remission (DoR)	Duration of remission (DoR) within 1 year after CD19 hsCAR-T infusion (Duration of remission (DOR) is defined as the duration from the date when the response criteria of CR or CRi is first met to the date of relapse or death due to ALL)	1 year
Secondary	Event free survival within 1 year	Event free survival within 1 year (Event free survival is defined as the time from start of the first infusion to the earliest of death from any cause or relapse)	1 year
Secondary	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])	Safety and tolerability of CD19 hsCAR-T: frequency and severity of adverse events, including, but not limited to, cytokine release syndrome (CRS) and macrophage activation syndrome (MAS)	6 months